Showing posts with label Mount Sinai Medical Center. Show all posts
Showing posts with label Mount Sinai Medical Center. Show all posts

Friday, November 9, 2018

Dementia-does vitamin E improve lives

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two


Vitamin E may slow down Alzheimer's and ease caregiving, according to a JAMA report. See how vitamin E improved daily activities in dementia, including shopping, preparing meals, planning and traveling. 




Difficulty with activities of daily living often affect Alzheimer's patients. Disruption to daily routine is one of the hardest burdens for caregivers. New research suggests that Vitamin E may slow functional decline in patients with mild-to-moderate Alzheimer's disease. This includes problems with daily activities such as:

  • Shopping
  • Preparing meals
  • Planning
  • Traveling
It appears to also decrease caregiver burden. There was no added benefit for memory and cognitive testing with the vitamin.

The research was performed by the faculty of Icahn School of Medicine at Mount Sinaiworking with Veterans Administration Medical Centers. The study is published online in the Journal of the American Medical Association.

The researchers investigated vitamin E as α-Tocopherol, an important fat-soluble antioxidant. Mary Sano, PhD, was the trial co-investigator, and professor in the department of psychiatry, Icahn School of Medicine at Mount Sinai, and director of research at the James J. Peters Veteran's Administration Medical Center, Bronx, New York. She said,

"Since the cholinesterase inhibitors [Aricept/donepezil, galantamine, rivastigmine], we have had very little to offer patients with mild-to-moderate dementia."

"This trial showed that vitamin E delays progression of functional decline by 19% per year, which translates into 6.2 months benefit over placebo."
The finding is valuable because vitamin E is easy to purchase at local drugstores and it is also inexpensive. The clinical trial investigators believe it can be recommended as a treatment strategy, based on the double-blind randomized controlled trial.

The Veteran's Administration Cooperative Randomized Trial of Vitamin E and memantine in Alzheimer's Disease (TEAM-AD examined the effects of vitamin E 2,000 IU/d, 20 mg/d of memantine, the combination, or placebo on Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory Score. Cognitive, neuropsychiatric, functional, and caregiver measures were secondary outcomes. A group of 613 patients with mild to moderate Alzheimer's disease were in the study, which was launched in August 2007 and finished in September 2012 at 14 Veterans Affairs Medical Centers. 

Dr. Sano previously led a study on Vitamin E in patients with moderately severe Alzheimer's disease. She found that the vitamin slowed disease progression in this group of patients as well.


Mount Sinai Medical Center, via Newswise.

Journal Reference:
  1. Maurice W. Dysken, Mary Sano, Sanjay Asthana, Julia E. Vertrees, Muralidhar Pallaki, Maria Llorente, Susan Love, Gerard D. Schellenberg, J. Riley McCarten, Julie Malphurs, Susana Prieto, Peijun Chen, David J. Loreck, George Trapp, Rajbir S. Bakshi, Jacobo E. Mintzer, Judith L. Heidebrink, Ana Vidal-Cardona, Lillian M. Arroyo, Angel R. Cruz, Sally Zachariah, Neil W. Kowall, Mohit P. Chopra, Suzanne Craft, Stephen Thielke, Carolyn L. Turvey, Catherine Woodman, Kimberly A. Monnell, Kimberly Gordon, Julie Tomaska, Yoav Segal, Peter N. Peduzzi, Peter D. Guarino. Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease. JAMA, 2014; 311 (1): 33 DOI:10.1001/jama.2013.282834


Monday, February 19, 2018

Does Vitamin E slow down Alzheimer's?

Caregivers, and healthcare professionals,here is some great information

Here is a great dementia resource for caregivers and healthcare professionals,

Your residents will love the Amazon Kindle Fire

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care  professionals to get an easyceu or two

Follow alzheimersideas on twitter

The Dementia Caregiver's Little Book of Hope [Kindle Edition]

Mount Sinai Medical Center, via Newswise.

Vitamin E may slow down Alzheimer's and ease caregiving, according to a JAMA report. See how vitamin E improved daily activities in dementia, including shopping, preparing meals, planning and traveling. 




Difficulty with activities of daily living often affect Alzheimer's patients. Disruption to daily routine is one of the hardest burdens for caregivers. New research suggests that Vitamin E may slow functional decline in patients with mild-to-moderate Alzheimer's disease. This includes problems with daily activities such as:

  • Shopping
  • Preparing meals
  • Planning
  • Traveling
It appears to also decrease caregiver burden. There was no added benefit for memory and cognitive testing with the vitamin.

Continued below video...

The research was performed by the faculty of Icahn School of Medicine at Mount Sinaiworking with Veterans Administration Medical Centers. The study is published online in the Journal of the American Medical Association.

The researchers investigated vitamin E as α-Tocopherol, an important fat-soluble antioxidant. Mary Sano, PhD, was the trial co-investigator, and professor in the department of psychiatry, Icahn School of Medicine at Mount Sinai, and director of research at the James J. Peters Veteran's Administration Medical Center, Bronx, New York. She said,

"Since the cholinesterase inhibitors [Aricept/donepezil, galantamine, rivastigmine], we have had very little to offer patients with mild-to-moderate dementia."

"This trial showed that vitamin E delays progression of functional decline by 19% per year, which translates into 6.2 months benefit over placebo."
The finding is valuable because vitamin E is easy to purchase at local drugstores and it is also inexpensive. The clinical trial investigators believe it can be recommended as a treatment strategy, based on the double-blind randomized controlled trial.

The Veteran's Administration Cooperative Randomized Trial of Vitamin E and memantine in Alzheimer's Disease (TEAM-AD examined the effects of vitamin E 2,000 IU/d, 20 mg/d of memantine, the combination, or placebo on Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory Score. Cognitive, neuropsychiatric, functional, and caregiver measures were secondary outcomes. A group of 613 patients with mild to moderate Alzheimer's disease were in the study, which was launched in August 2007 and finished in September 2012 at 14 Veterans Affairs Medical Centers. 

Dr. Sano previously led a study on Vitamin E in patients with moderately severe Alzheimer's disease. She found that the vitamin slowed disease progression in this group of patients as well.




Thursday, July 21, 2011

'Prevention is better than cure for Alzheimer's disease

Here is a great dementia resource for caregivers and healthcare professinals,

Here is information on being the best caregiver you can be

Here is a way for nurses administrators, social workers and other health care professionals to get an easyceu or two

Here are more interesting dementia brain boosting activities



By Robert Bazell
Chief science and health correspondent

NBC News NBC News

Curing Alzheimer’s disease may be impossible and the best hope to control the disease may require beginning treatments as much as 20 years before the onset of symptoms. It could take decades to find effective therapies for the brain-wasting disease.

That is the view of Dr. Sam Gandy, a highly respected Alzheimer's expert at Mount Sinai Medical Center in New York. Writing a perspective article titled “Prevention is Better than Cure” in this week’s issue of the journal Nature, Gandy offers an argument that will likely dominate much of the discussion next week when 4,000 researchers gather in Paris for the Alzheimer’s Association’s Annual International Conference.

Gandy notes it has been more than a century since the German psychiatrist Alois Alzheimer described the condition that bears his name. Dr. Alzheimer discovered the disease in a 51-year-old woman called Auguste D. After her death, Alzheimer noticed her brain was speckled with plaques of a protein now known as amyloid-beta peptide.

In recent decades, on the basis of sound evidence, many scientists have concluded that amyloid plaques play a key role in causing the devastation of Alzheimer’s disease. The pharmaceutical industry has produced drugs and vaccines designed to clear the plaques from the brain. The problem is, in a few large studies the plaque goes away, but the symptoms of the disease continue to worsen.

One camp among Alzheimer’s researchers believes this shows that amyloid is simply not the cause. But the majority of researchers, like Gandy, believe that once the plaque appears the damage to the brain is too great to undo and the only hope is to prevent it. Recent studies using brain scans, spinal fluid and blood samples have been searching for signs that appear before the psychological tests reveal the onset of dementia. Much of this work is centered on the handful of families where some members carry a dominant gene variation that causes them to get Alzheimer’s in their 30s, 40s or 50s, but that type of screening is expected to become more common.

It is increasingly apparent from these studies that many of these changes occur as much as 20 years before the symptoms of the disease. Alzheimer's can progress at different rates but typically develops through different stages, beginning with mild cognitive impairment — forgetting familiar words or losing common objects — to difficulty performing tasks to severe dementia and the inability to carry on a conversation or control movements.

Scientists believe it might be necessary to administer amyloid-lowering drugs early in the course of the disease — long before it is anything that could be called a disease. It also seems likely that it will take years to prove whether any drugs work.

However, getting started with any course of treatment quickly is vital. By 2050, it's estimated that as many as 16 million Americans will have the disease. Most people survive about four to eight years after diagnosis, but some can live as long as 20 years with the disease, according to the Alzheimer's Association.

Gandy writes that “we should not be discouraged by the prospect of another decade or two of work” to know whether controlling amyloid is the key to controlling Alzheimer’s disease. “Prophylactic intervention,” he writes, “is now the best hope.”
Blog Flux Directory
alzheimersideas - whereIstand.com

Fitness is important in dementia prevention. Click below for more info